News | June 17, 2007

Early Palliative Care Linked To Shorter Stays In Intensive Care

June 18, 2007 — Early palliative care interventions can reduce the length of stay for seriously ill patients in the medical intensive care unit (ICU) by more than seven days without having an impact on mortality rates, according to the University of Rochester Medical Center.

Historically, palliative care was most strongly associated with end-of-life care with palliative care specialists seeing patients very late in their illness, often after patients had already been in intensive care for two weeks or more or after all other life-prolonging interventions had been exhausted.

The Rochester study, published in the June issue of Critical Care Medicine, sought to address this gap by instituting and evaluating the impact of early proactive palliative care consultations on high-risk patients' length of stay in the ICU, length of hospital stay, and mortality.

The study looked at the impact of palliative care interventions on all 191 patients admitted to the ICU at Strong Memorial Hospital in Rochester, NY, between March 2004 and March 2005 identified as having a serious illness and at high risk of dying. The patients were screened by physician and nursing palliative care leaders within 72 hours of admission.

Patients admitted during first phase of the study received a palliative care consultation only after a ICU physician referral as was the standard practice prior to the study. High-risk patients admitted during the second phase received a proactive palliative care consultation shortly after admission.

The study found that patients in the proactive phase had significantly shorter lengths of stay in the ICU than those in the first phase, while there was no difference between the two groups on total length of stay in the hospital or mortality rates.

In addition to improving quality of care, proactive palliative care consultation in the ICU has an unintended, yet relevant, benefit of financial savings. Extrapolating from the study's findings, the intervention potentially saved approximately 1,400 ICU patient days at a savings of around $450 per day.

For more information: www.urmc.rochester.edu

Related Content

Videos | Breast Imaging | May 08, 2018
ITN Associate Editor Jeff Zagoudis speaks with Karen Hou, M.D., breast radiologist at Northwestern Medicine Central D
Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow
Technology | Mammography | December 11, 2017
Siemens Healthineers unveiled the new Mammomat Revelation premium mammography platform at the 2017 Radiological Society...
Hologic rings Nasdaq bell for breast cancer awareness
News | Breast Imaging | October 02, 2017
Hologic Inc. announced that Steve MacMillan, the company's chairman, president and CEO, joined selected employees to...
Hologic Announces Availability of Brevera Breast Biopsy System With CorLumina Imaging Technology
Technology | Breast Biopsy Systems | August 31, 2017
Hologic Inc. announced U.S. commercial availability of the Brevera breast biopsy system with CorLumina imaging...
Top list of stories, article, videos for breast imaging.
Feature | Breast Imaging | August 30, 2017 | Dave Fornell
August 30, 2017 — This is a list of the top breast imaging content so far for 2017.
Hologic, ECR 2017, breast cancer screening solutions, Affirm prone biopsy system

The Affirm prone biopsy system. Image courtesy of Hologic.

News | Breast Imaging | March 14, 2017
Hologic Inc. highlighted its portfolio of innovative breast cancer screening and interventional products, including new...
Sponsored Content | Videos | Women's Health | November 16, 2016
The purpose of this exploratory video roundtable is to examine the state of breast biopsies today and to communicate...
stereotactic breast imaging

This image shows a 52-year-old patient with benign calcifications in her pre-stereotactic breast biopsy screening.

Feature | Breast Biopsy Systems | November 01, 2016 | By Laura Shepardson, M.D.
Recently, I was invited to participate in a...
Hologic, FDA approval, launch, Affirm prone biopsy system, breast cancer, women's health
Technology | Breast Biopsy Systems | April 21, 2016
Hologic Inc. announced the U.S. Food and Drug Administration (FDA) clearance and commercial launch of the Affirm prone...
Overlay Init